加蓬半农村地区HIV病毒学失败及耐药高发与多替拉韦方案疗效启示
该研究纳入2018至2019年加蓬弗朗斯维尔219名接受抗逆转录病毒治疗的成人,评估病毒载量抑制和获得性耐药。总体病毒载量抑制率为57.1%,HIV耐药总患病率为21.9%,在治疗失败者中达67.2%。含多替拉韦的一线方案对多数耐药病毒预期无效,提示资源有限地区ART管理面临挑战。
要点
- 半农村地区ART患者病毒载量抑制率仅57.1%,总体HIV耐药患病率21.9%。
- 治疗失败者中HIV耐药高达67.2%,84.6%耐药序列同时携带NRTI和NNRTI突变。
- 含替诺福韦/拉米夫定/多替拉韦的一线方案仅对5/39耐药病毒预期有完全活性。
核心结论
- 加蓬半农村地区接受ART的成人病毒载量抑制率很低,HIV耐药负担高,已影响当前和新推荐ART策略的疗效。
研究设计与样本
- 研究为横断面研究,2018至2019年在加蓬弗朗斯维尔招募219名接受ART的成人,中位治疗时间27个月,216/219例使用一线ART。
主要发现
- 总体病毒载量抑制(VL<1000 copies/mL)率为57.1%(95%CI 50.5-63.8),女性为59.4%(51.4-67.5),男性为52.2%(40.3-64.2)。
- 研究人群中HIV耐药总患病率为21.9%,治疗失败者中为67.2%。
- 84.6%的耐药序列同时存在NRTI和NNRTI突变。
- 含替诺福韦二吡呋酯/拉米夫定/多替拉韦的一线方案仅对5/39例耐药病毒预期有完全活性。
临床怎么用
- 在资源有限地区应加强HIV病毒载量监测和耐药检测,以识别治疗失败并指导方案调整。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The projected UNAIDS goal of ending AIDS by 2030 requires significant global efforts to improve current and future ART strategies. In this study, we assessed viral load (VL) suppression and acquired drug resistance, as well as future efficacy of dolutegravir-based combinations for patients living in semi-rural regions of Gabon. METHODS: Eligible study participants were adults receiving ART and recruited between 2018 and 2019 in Franceville, Gabon. VL testing was conducted to assess VL suppression and HIV drug resistance (HIVDR) testing was performed to identify resistance mutations and assess their impact on ongoing and future ART regimens. RESULTS: We recruited 219 participants overall. The median time on ART was 27 months and 216/219 participants were on first-line ART. VL suppression (VL < 1000 copies/mL) was 57.1% (95% CI 50.5-63.8) overall; 59.4% (51.4-67.5) and 52.2% (40.3-64.2) for women and men, respectively. The overall prevalence of HIVDR was 21.9% among the study population and 67.2% among those who failed ART. Presence of both NRTI and NNRTI mutations was found in 84.6% of sequences with drug resistance mutations, and full activity of a dolutegravir-based first-line regimen including tenofovir disoproxil fumarate/lamivudine/dolutegravir was expected only for 5/39 patients with a resistant virus. CONCLUSIONS: This study shows a very low rate of VL suppression in a semi-rural context in Africa. Moreover, the high burden of HIVDR has affected both current and newly recommended ART strategies. Better management of ART in resource-limited settings is still a challenging ambition.
引用
- Engone-Ondo JD, Mouinga-Ondémé A, Lékana-Douki SE, et al. High rate of virological failure and HIV drug resistance in semi-rural Gabon and implications for dolutegravir-based regimen efficacy. J Antimicrob Chemother. 2021. PMID: 33367796. doi:10.1093/jac/dkaa537
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。